Insight

The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer – Annals of Oncology

A. Alvarez Secord/dukecancerinstitute.org

Dec 3, 2024, 17:07

The Efficacy and Safety of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive Ovarian Cancer – Annals of Oncology

Annals of Oncology shared a recent article by A. Alvarez Secord on X:

“New article in press: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial.”

Title: The Efficacy and Safety of Mirvetuximab Soravtansine in FRα-Positive, Third-Line and Later, Recurrent Platinum-Sensitive Ovarian Cancer: The Single-Arm Phase 2 PICCOLO Trial

Authors: A. Alvarez Secord, S.N. Lewin, C.G. Murphy, S.C. Cecere, A. Barquín, F. Gálvez-Montosa, C.A. Mathews, G.E. Konecny, I. Ray-Coquard, A. Oaknin, M. J. Rubio Pérez, A. Bonaventura, E.J. Diver, S.-A. Ayuk, Y. Wang, B.R. Corr and V. Salutari

Mirvetuximab Soravtansine

More posts featuring Annals of Oncology.

A. Alvarez Secord A. Barquín Annals of Oncology B.R. Corr C.A. Mathews C.G. Murphy cancer E.J. Diver efficacy F. Gálvez-Montosa G.E. Konecny Mirvetuximab Soravtansine OncoDaily Oncology Ovarian Cancer PICCOLO Trial Platinum-Sensitive S.-A. Ayuk S.C. Cecere S.N. Lewin safety V. Salutari Y. Wang

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer